Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy
Completed · Not applicable
Conditions studied: Diabetes Mellitus
In brief
Type I diabetes (T1DM) is the second most common chronic illness effecting children in the USA. Worldwide, Type I diabetes is increasing in incidence, and its underlying etiology remains elusive. Nevertheless, recent data supports the notion that early and intensive management of Type I diabetes can 1) decrease long-term complications of diabetes; and 2) may significantly improve beta cell function and insulin secretion over ensuing years. To this end, we propose using insulin pump therapy to preserve and/or enhance residual endogenous B-cell secretory capacity among patients with newly diagnosed Type 1 DM. Furthermore, we anticipate that early use of an insulin pump will improve glycemic control beyond that achieved with standard multiple daily injection (MDI) therapy, and will be well-tolerated by the patient. These data will provide important pilot information to explore the potential role of intensive insulin pump therapy in the treatment of children newly diagnosed with Type I diabetes. The specific aim of this study is to test the following hypothesis: Early use of insulin pump therapy is effective in preserving or enhancing residual endogenous pancreatic B-cell secretory capacity among patients with newly diagnosed T1DM: Moreover, early use of an insulin pump will improve glycemic control beyond that achieved with standard multiple injection therapy, and will be well-tolerated by the patient.
Key facts
- Study ID
- NCT00574405
- Run by
- Arkansas Children's Hospital Research Institute
- People needed
- 24
- Starts
- 2005-04-01
- Expected to finish
- 2011-03-01
- Last updated by the study team
- 2017-09-13
Who can join
Age: 8 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Medical history and clinical presentation consistent with the diagnosis of Type 1 DM.
- Age: 8-18 years
You may not qualify if…
- Clinical presentation consistent with Type 2 DM.
- History of other chronic systemic inflammatory or autoimmune disease or other severe medical conditions.
- Concurrent pregnancy.
- Participation in other research protocols or use of other investigational agents within 30 days of enrollment.
Where it is running
- Arkansas Children's Hospital/Research Institute — Little Rock, Arkansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.